A study detailed the landscape of lung adenocarcinoma progression. MK-1084 as monotherapy and in combination with pembrolizumab is effective in patients with NSCLC. The timing of chemotherapy given to patients with SCLC does not have a statistically significant impact on OS. The timing of chemotherapy given to patients with SCLC does not have a statistically significant effect on OS. Lung cancer screening discussions are not happening as often as they could be among health care providers. The postoperative comfort scale has good reliability and validity, and can be used to assess patients with lung cancer. Just under a quarter of a million new cases of lung cancer were diagnosed in 2023, with 10-20% in non-smokers. Preoperative ctDNA has prognostic value for determining long-term prognosis for NSCLC. Clinical trial investigators should use a mindful approach when planning to assess HRQOL in NSCLC. It is reasonable to upgrade ECE of tumor in lymph nodes from R0 to incomplete resection. Worse clinical outcomes and higher risk for brain metastasis are more likely to happen in patients with metastatic NSCLC. Occupational asbestos exposure leads to shorter survival in patients with malignant mesothelioma. Guideline-concordant therapy remains underused in most mesothelioma patients. Researchers looked at unique features in epidemiology, risk factors, and biology of lung cancer in women. Opportunistic screening for lung cancer helped lower the risk of death related to the disease in China. Low-dose computed tomography can reduce the number of deaths from lung cancer in Brazil. The use of tobacco negatively affects survival outcomes in patients with advanced NSCLC. Patients with EGFR-positive metastatic NSCLC whose disease progressed following first-line treatment have worse outcomes. Patient selection for perioperative immunotherapies may be determined by specific intratumoral immune cells. A study explored the potential benefits of combining first-generation EGFR-TKI with chemotherapy as neoadjuvant treatment.